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The present study was undertaken to evaluate the possible protective eﬀects of simvastatin (SMV) against oxidative stress in
streptozotocin- (STZ)-induced diabetic rats. Diabetes was induced experimentally in rats by i.p. injection of STZ in a dose of
60mg/kg bwt. After 5 weeks of STZ injection, there were apparent reductions in the animal body weight and signiﬁcant increase
in blood glucose, HbA1c, urea, creatinine, AST, ALT, and lipid proﬁles with a concomitant decrease in total hemoglobin, plasma
glutathione and vitamin C as compared to the control group. The treatment with SMV at a dose (10mg/kg, orally) normalized all
the above-mentioned biochemical parameters in STZ-induced diabetic rats. In vitro studies conﬁrmed the free radical scavenging
and antioxidant activity of SMV. Therefore, the present results revealed that SMV has a protective eﬀect against STZ-induced
oxidative damage by scavenging the free radicals generation and restoring the enzymatic and nonenzymatic antioxidant systems.
1.Introduction
Diabetes is a major threat to global public health, and the
number of diabetic patients is rapidly increasing world-wide.
More than 220 million people worldwide have diabetes and
this number is likely to be more than double by the year of
2030[1].Apartfromthis,morethan60%oftheworldpopu-
lation with diabetes will come from Asia [2]. It has already
beenestablishedthatchronichyperglycemiaofdiabetesisas-
sociatedwithlong-termdamage,dysfunction,andeventually
failure of organs, especially the kidneys, nerves, heart, eyes,
andbloodvessels[3].About50%ofindividualswithdiabetes
are aﬀected with one or more of the above complications.
Oxidative stress plays an important role in chronic com-
plications of diabetes and is postulated to be associated with
increased lipid peroxidation (LPO) [4, 5]. Streptozotocin
(STZ) is frequently used to induce diabetes mellitus in ex-
perimental animals through its toxic eﬀects on pancreatic β-
cells [6]. The cytotoxic action of STZ is associated with the
generation of reactive oxygen species (ROS) causing oxida-
tive damage [7]. Oxidative stress increases due to several fac-
tors: enhancement of glucose auto-oxidation, stimulation of
the polyol pathway, production of advanced glycation prod-
ucts,andreductioninantioxidantdefenses,suchasdepletion
of cellular antioxidant levels and decreased antioxidative en-
zyme activity [3, 8]. In diabetes there are signiﬁcant changes
such as increased LPO, dyslipidemia, and irregularities in the
metabolismofproteins,lipids,andcarbohydrates[9].Chem-
icals with antioxidant properties and free radical scavengers
mayhelpintheregenerationofβ-cellsandprotectpancreatic
islets against cytotoxic eﬀects of STZ [6, 10].
3-Hydroxy-3-methylglutarylcoenzymeA(HMG-CoA)re-
ductase inhibitors (statins) including simvastatin (SMV)
have been previously demonstrated in diabetic patients with2 Journal of Lipids
their ability to reduce albuminuria [11–13]. Furthermore,
administration of statins in experimental diabetes has previ-
ously been reported to be associated with a reduction in the
renal expression of the prosclerotic cytokine, transforming
growth factor-β1(T G F - β1) [14, 15], improve wound healing
[16], and improve endothelial function in experimental dia-
betic rats [17]. Furthermore, a meta-analysis provided evi-
dence that statins reduce the progression of retinopathy [18]
and nephropathy [19].
One of the pleiotropic mechanisms receiving much at-
tention is the antioxidant eﬀect of statins [20, 21]. Mechani-
sms for this may be due to the inhibition of oxidant forma-
tion by aﬀecting NADPH-oxidase, blocking of the eﬀects of
ROS by upregulation of antioxidant enzymes, or an increase
in nitric oxide bioavailability which neutralizes radicals [22].
ROSs, including free radicals such as HO• and O2
•−,a n d
m o l e c u l e ss u c ha sh y d r o g e np e r o x i d e ,a r ei n v o l v e da n dc o n -
tributetothedevelopmentofatherosclerosis[23].Important
sources of ROS are NADPH oxidases from endothelial cells,
smooth muscle cells, ﬁbroblasts, and inﬁltrated monocytes/
macrophages[24].Therefore,thepresentstudy wasdesigned
to investigate the eﬀects of simvastatin on oxidative stress
m a r k e r sa sw e l la so nt h ea n t i o x i d a t i v ed e f e n s es y s t e mi n
STZ-induced diabetic rats.
2.MaterialsandMethods
2.1. Chemicals. Simvastatin (SMV), Streptozotocin (STZ),
hydrogen peroxide, glutathione, 5,5 -dithio-bis-(2-nitroben-
zoic acid), thiobarbituric acid (TBA), 1,1,3,3-tetraethoxy-
propane, glutathione-reduced form, glutathione reductase,
oxidized glutathione (GSSG), NADPH-tetra salt, and ethyle-
nediamine tetra acetic acid (EDTA) disodium salt were pur-
chased from Sigma-Aldrich Chemical (St Louis, MO, USA).
Catalase (CAT), superoxide dismutase (SOD), and gluta-
thione peroxidase (GSH-Px) reagent assay kits were purchas-
ed from Cayman chemical (MI, USA). Glucotest (glucose
urine strips) was purchased from Roche Diagnostics (Mann-
heim, Germany). All other chemicals were of the highest
grade available commercially.
2.2. Experimental Animals. Forty male Sprague-Dawley rats,
weighing 200–220g, were obtained from King Fahd Medical
Research Center, King Abdulaziz University (Jeddah, Saudi
Arabia). Guides for the care and use of laboratory animals
were approved by the local ethics committee at the King
Abdulaziz University. Rats were housed in wire-ﬂoored cages
under a 12h light-dark cycle for at least 7 days prior to treat-
ment and were fed standard laboratory chow and tap water
ad libitum. The room temperature was kept at 22 ± 2◦C. All
stressful conditions were avoided. Rats were fasted overnight
prior to the study and housed in mesh-bottomed cages to
minimize coprophagia. Except for the last hour, water was
supplied ad libitum.
2.3. Experimental Induction of Diabetes. Animals were fasted
overnight and diabetes was induced by a single intraperi-
toneal injection of a freshly prepared solution of STZ
(60mg/kg)in0.1mol/Lcitratebuﬀer(pH4.5)[25].Thedos-
ing volume was 1mL/kg. To prevent fatal hypoglycemia, rats
werekepton5%glucosesolutionfor24hafterSTZinjection.
Successfulinductionofdiabeteswasconﬁrmedbymeasuring
thefastingbloodglucoseconcentrationinrats6hafterinjec-
tion of STZ. Rats with a fasting blood glucose level >250mg/
dL were considered diabetic and included in the present
study.
2.4. Experimental Design. One week after the administration
of STZ and citrate buﬀer, control and diabetic rats were ran-
domly assigned to treatments with SMV or glibenclamide.
Rats were divided into ﬁve groups, with eight rats in each
group, as follows: (i) Group I, control rats receiving vehicle
solution (citrate buﬀer; 1mL/kg/day); (ii) Group II, control
rats receiving SMV (10mg/kg/day) only; (iii) Group III, dia-
betic control rats injected with STZ (60mg/kg bodyweight,
i.p.) only; (iv) Group IV, diabetic rats treated with SMV
(10mg/kg/day) in aqueous solution via an intragastric tube
3 days after STZ treatment and continued for 5 weeks [26];
and (v) Group V, diabetic rats treated with glibenclamide
(0.60mg/kg/day) in aqueous solution daily via an intragas-
tric tube for 5 weeks.
The following parameters were assessed in each of the
study groups during the treatment period: daily ﬂuid and
food consumption, weekly body weight, and blood glucose
concentration (Glucostix strips tested in a glucometer; Ab-
bott Laboratories, Medisense Products, Bedford, MA, USA).
Food consumption was determined by subtracting leftovers
from the diet provided to rats at 2-day intervals.
After the last treatment (5 weeks), rats were fasted over-
night and sacriﬁced by cervical decapitation. Blood was col-
lected in two separate tubes, with and without anticoagulant,
for the estimation of glucose, hemoglobin, HbA1c, lipid pro-
ﬁles, liver and kidney function tests. Liver, and kidney tissues
wereexcisedimmediatelyfromtheratsandstoredinice-cold
containers.
2.5. Preparation of Liver and Kidney Homogenates. After
blood sample collection, the animals were killed and then
the liver and kidneys were removed immediately and placed
in ice-cold 0.1M phosphate buﬀer saline (PBS) with pH 7.5.
The tissues were then blotted dry and weighted. A 10% tissue
homogenates (w/v) of the liver and kidney were prepared in
PBS. Homogenates were then centrifuged at 1000rpm for
10mininacoolingcentrifugetoremovethecelldebris.Then
the supernatants were placed in −80◦C until further use to
determine antioxidant enzymes activities and LPO. Protein
was estimated by the method of Lowry et al. [27].
2.6. In Vitro Antioxidant Study
2.6.1. Total Antioxidant Activity Determination. The antioxi-
dant activity of SMV was determined according to the thio-
cyanate method [28]. Ten milligrams of SMV was dissolved
in 10mL water. SMV at various concentrations (25, 50 and
75μg/mL) or standard sample (α-tocopherol) in 2.5mL of
potassium phosphate buﬀer (0.04M, pH 7.0) was added toJournal of Lipids 3
linoleic acid emulsion. Five-milliliter linoleic acid emulsion
consistsof17.5μgtween-20,15.5μLlinoleicacid,and0.04M
potassium phosphate buﬀer (pH 7.0). On the other hand,
5.0mL control consists of 2.5mL linoleic acid emulsion and
2.5mL potassium phosphate buﬀer (0.04M, pH 7.0). The
mixed solution was incubated at 37◦C in a glass ﬂask and in
thedark.Afterthemixturewasstirredfor3min,theperoxide
valuewasdeterminedbyreadingtheabsorbanceat500nmin
a spectrophotometer, after reaction with FeCl2 and thiocya-
nate at intervals during incubation. During the linoleic acid
oxidation, peroxides formed. These compounds oxidize Fe2+
to Fe3+.ThelatterFe3+ ionsformcomplexwithSCN−,whic h
had maximum absorbance at 500nm. Therefore, high absor-
bance indicates high linoleic acid oxidation. The solutions
without SMV or standards were used as blank samples. All
data about total antioxidant activity are the average of dupli-
cate analyses. The inhibition of LPO in percentage was calcu-
lated by following equation:
% Inhibition =
(A0 −A1)
A0

× 100, (1)
where A0 was the absorbance of the control reaction and A1
was the absorbance in the presence of the sample of SMV.
2.6.2. DPPH Scavenging Activity. The free radical scavenging
activity of SMV, buthylated hydroxyanisole (BHA), and
α-tocopherol were measured using the method of Shimada
et al. [29] with a slight modiﬁcation. A 0.1mM solution
of 1,1-diphenyl-2-picryl-hydrazyl (DPPH•) in ethanol was
prepared and 1mL of this was added to 3mL of SMV solu-
tion in ethanol at diﬀerent concentrations (20–80μg/mL).
After 30min, a decrease in absorbance was measured at
517nm and the actual decrease in absorption induced by
the test compound was calculated by subtracting that of the
control.
2.7. Biochemical Analysis
2.7.1. Plasma Glucose Assay. P l a s m ag l u c o s el e v e l sw e r ee s t i -
mated using a commercial kit (Sigma Diagnostics Pvt. Ltd.,
Baroda, India) by the method of Trinder [30].
2.7.2. Total Hemoglobin (Hb) and Glycosylated Hemoglobin
(HbA1c)Assays. TotalHbandHbA1c wereestimatedbyDia-
gnostic kit-Bio Systems (Costa Brava, Spain).
2.7.3.PlasmaLipidProﬁle. Plasmatotalcholesterol(TC),tri-
glycerides (TGs), and HDL-cholesterol (HDL-C) levels were
determined by enzymatic colorimetric methods. The TC
concentration was proportional to the dye product formed
by the reaction of the hydrogen peroxide released with 4-
aminophenazone and phenol reagent, measured at 540nm.
Plasma HDL-C was determined by precipitation with phos-
photungstate-MgCl2 solution [31]. The enzymatic method
used for determination of cholesterol in the supernatant
used kits (Cholesterol Oxidase/Peroxidase kit) is supplied by
BioSystems (Barcelona, Spain). Determination of TG level
was based on TG hydrolysis by lipase, where the glycerol
formed used glycerol kinase, phosphoglycerol oxidase, and
peroxidase to form hydrogen peroxide, which reacts with 4-
aminophenazone and 4-chlorophenol to produce a complex
that can be measured at 620nm using an autoanalyser
(model 7150; Hitachi, Tokyo, Japan).
2.7.4. Liver Function Tests. The activities of serum hepatic
marker enzymes, namely, aspartate aminotransferase (AST)
and alanine aminotransferase (ALT) were assayed in serum
using standard kits from Merck using colorimetric method
[32]. The results were expressed as U/L.
2.7.5. Kidney Function Tests. Serum creatinine and urea were
determined at 37◦C colorimetrically by the modiﬁed Jaﬀe
method and the modiﬁed Berthelot-Searcy enzymatic
method, respectively. They were assayed using reagents ob-
tained from assay kits (Quimica Clinica Applicada, Spain).
Urinary protein was quantiﬁed by the Biuret method using
bovine serum albumin as the standard.
2.7.6. Determination of Plasma Antioxidants. Reduced gluta-
thione (GSH) was estimated by the method of Ellman [33].
A 0.1mL of plasma was precipitated with 5% TCA. The con-
tents were mixed well for complete precipitation of proteins
andcentrifuged.Toanaliquotofclearsupernatant,2.0mLof
0.6mM 5,50-dithiobis-2-nitrobenzoic acid (DTNB) reagent
and 0.2M phosphate buﬀer (pH 8.6) were added to obtain a
ﬁnal volume of 4.0mL. The absorbance was read at 412nm
against a blank containing 5% TCA instead of sample. A
series of standards treated in a similar way were also run
to determine the glutathione content. The amount of gluta-
thione was expressed as mg/dL in plasma.
Ascorbic acid (Vitamin C) concentration was measured
by the method of Omaye et al. [34]. To 0.25mL of plasma,
0.75mL of 6% TCA was added and centrifuged (3500g,
20min). To 0.25mL of supernatant, 0.25mL of dinitrophen-
ylhydrazone (DNPH) reagent (2% DNPH and 4% thiourea
in 4.5M sulphuric acid) was added and incubated for 3h at
room temperature. After incubation, 1.25mL of 85% sul-
phuric acid was added and color developed was read at
530nm after 30min.
2.7.7. Lipid Peroxidation (LPO) Assay. LPO was determin-
ed by measuring thiobarbituric acid reactive substances
(TBARS) content in tissue homogenates according to the
method of Uchiyama and Mihara [35], with some modiﬁca-
tions. Brieﬂy, 0.01g liver or kidney tissue was homogenized
with 0.9mL of 1.15% KCl solution and the TBARS content
was measured spectrophotometrically at 532nm. The
TBARS content was calculated based on a standard curve
using 1,1,3,3-tetraethoxypropane as a standard.
2.7.8. Reduced Glutathione (GSH) Assay. GSH was measured
in liver and kidney tissue homogenates by the reaction of the
sulphydryl groups (SH) in the nonprotein fractions with 5,5-
dithiobis-(2-nitrobenzoic acid; DTNB or Ellman’s reagent).
The GSH levels were compared with a standard curve pre-
pared using diﬀerent known concentrations of GSH.4 Journal of Lipids
The product was measured spectrophotometrically at
412nm [33].
2.7.9. Enzymatic Antioxidants Assays. Superoxide dismutase
(SOD)activity wasdetermined in homogenatesand erythro-
cytes according to the methods of S. Marklund and G.
Marklund [36]. A colorimetric assay was performed that in-
volvedgenerationofsuperoxidebypyrogallolauto-oxidation
and the inhibition of superoxide-dependent reduction of the
tetrazolium dye 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl-
tetrazolium bromide (MTT) to formazan by SOD, measured
at 570nm. The amount of MTT formazan was calculated by
using a molar extinction coeﬃcient E570 of 17000L/mol per
cm. One unit of SOD was deﬁned as the amount of protein
required to inhibit MTT reduction by 50%.
Catalase (CAT) activity was measured according to the
method described by Aebi [37]. One unit of CAT activity was
deﬁned as the amount of enzyme required to decompose
1mmolH2O2 in1min.A50mLaliquotoftissuesupernatant
was added to a cuvette containing 1.95mL of 50mmol/L
phosphate buﬀer (pH 7.0). The reaction was started by the
addition of 1.0mL freshly prepared 30mmol/L H2O2.T h e
rate of decomposition of H2O2 was measured spectrophoto-
metrically at 240nm for 1min.
The activity of glutathione peroxidase (GSH-Px) was
determined according to the method of Lawrence and Burk
[38]. The assay mixture consisted of 2.0mL of 75mmol/L
phosphate buﬀer (pH 7.0), 50mL glutathione, 0.1mL of
30units/mL glutathione reductase, 0.1mL of 15mmol/L
EDTA, 0.1mL of 3mmol/L NADPH, and the appropriate
amount of tissue supernatant to reach a ﬁnal volume of
3.0mL. The reaction was started by the addition of 0.1mL of
7.5mmol/L H2O2. The rate of change of absorbance during
the conversion of NADPH to NADP+ was recorded spectro-
photometrically at 340nm for 3min. The GSH-Px activity
for tissues was expressed as mmol GSH oxidized/min per mg
protein.
2.7.10. Determination of Protein Content. The protein con-
tent of tissue homogenates was determined by the Lowry
protein assay using bovine serum albumin as the standard
[27].
2.8. Statistical Analysis. The Graph Pad (ISI Software, Phila-
delphia, PA, USA) computer program was used to conduct
regression analysis and to plot collected data. Data are ex-
pressed as the mean ± SEM. Results were assessed using one-
way ANOVA followed by Tukey-Kramer multiple compari-
sons tests using Graph Pad Instat (Version 3.06; Graph Pad
Software La Jolla, CA, USA). P<0.05 was used as the cri-
terion for signiﬁcance.
3. Results
3.1. In Vitro Antioxidant of SMV. The eﬀects of various
amounts of SMV on the peroxidation of linoleic acid emul-
sion are shown in Table 1. The antioxidant activity of SMV
in the concentration of 40μg/mL and 80μg/mL was greater
Table 1: In vitro total antioxidant and free radical scavenging acti-
vities of simvastatin (SMV), buthylated hydroxyanisole (BHA), and
α-tocopherol (α-Toc).
Groups
Total antioxidant activity
(Inhibition of lipid
peroxidation %)a
Free radical scavenging
activity (DPPH•μM)b
α-Toc
(80μg/mL) 46.2 76
BHA
(80μg/mL) 93.7 83
SMV
(20μg/mL) 41.2 38
SMV
(40μg/mL) 60.2 44
SMV
(80μg/mL) 98.3 72
Data are the mean ± SEM for eight animals in each group.
aThe antioxidant activity of diﬀerent doses of simvastatin (20–80μg/mL)
was determined by the thiocyanate method. The peroxide values were
determined by reading the absorbance at 500nm after reaction with FeCl2
and thiocyanate. bFree radical scavenging activity of diﬀerent doses of SMV,
BHA, and α-tocopherol by 1,1-diphenyl-2-picrylhydrazyl radicals.
Table 2: Eﬀect of simvastatin (SMV) and glibenclamide supple-
mentation on ﬂuid and food intake and body weight of rats in the
diﬀerent experimental groups.
Groups
Fluid
intake
(mL/day)
Food intake
(g/day)
Weight gain
(g/day)
Control 28 ± 3 15.3 ± 0.2 4.90 ± 0.03
SMV 33 ± 2 18.2 ± 0.42 4.41 ± 0.06
Diabetic 96 ± 5∗ 25.7 ± 0.3∗ 2.96 ± 0.04∗
Diabetic + SMV 46 ± 4∗# 22.1 ± 0.5∗ 3.30 ± 0.05∗
Diabetic +
Glibenclamide 36 ± 2∗# 23.0 ± 0.2∗ 3.71 ± 0.03∗#
Data are the mean ± SEM for eight animals in each group.
∗P<0.001 compared with the control group.
#P<0.05 compared with the untreated diabetic group.
than that of α-tocopherol 80μg/mL and showed 60.2% and
98.3% inhibition on peroxidation of linoleic acid, respec-
tively, greater than that of α-tocopherol (46.2%). The antiox-
idant activity of SMV in the concentration of 20μg/mL was
closetothatofα-tocopherolandshowed41.5%inhibitionon
peroxidation of linoleic acid. Also, Table 1 illustrates a sig-
niﬁcant (P<0.05) decrease in the concentration of DPPH
radicalduetothescavengingability ofstandardsandSMVin
a concentration-dependant manner. The scavenging eﬀect of
SMV and standards on the DPPH radical decreased in the
order of BHA >α -tocopherol > SMV. These results indi-
cated that SMV and standards have a noticeable eﬀect on
scavenging free radical. Free radical scavenging activity also
increased with increasing concentration of SMV in a con-
centration-dependant manner.
3.2. Fluid and Food Intake, Bodyweight, and Organ Weight.
Table 2 showssigniﬁcantdiﬀerencesinﬂuidandfoodintakesJournal of Lipids 5
Table 3: Eﬀect of simvastatin (SMV) and glibenclamide supple-
mentation on blood glucose, haemoglobin (Hb) and glycosylated
haemoglobin (HbA1c)o fr a t si nd i ﬀerent experimental groups.
Groups Blood glucose
(mg/dL) Hb (g/dL) HbA1c (%
Hb)
Control 84.3 ± 4.2 12.8 ± 0.41 5.8 ± 0.32
SMV 87.5 ± 3.6 13.0 ± 0.36 6.1 ± 0.21
Diabetic 336 ± 9.8∗ 9.8 ± 0.43∗ 12.7 ± 0.5∗
Diabetic + SMV 260 ± 7.3∗# 10.6 ± 0.52 10.2 ± 0.33∗#
Diabetic +
Glibenclamide 127.5 ± 6.4∗# 12.3 ± 0.48# 6.7 ± 0.03#
Data are the mean ± SEM for eight animals in each group.
∗P<0.001 compared with the control group.
#P<0.05 compared with the untreated diabetic group.
and bodyweight gain between control and diabetic rats. In-
creased ﬂuid and food intakes and decreased bodyweight
were observed in diabetic rats compared with control rats.
Administration of SMV or glibenclamide tended to increase
bodyweight to that seen in untreated control rats and the
eﬀect was more pronounced in the group of rats treated with
glibenclamide. There was no signiﬁcant change in control
rats treated only with SMV.
3.3. Blood Glucose, Total Hb, and HbA1c. Levels of blood
glucose, total Hb, and HbA1c in control and diabetic rats are
given in Table 3.
The fasting blood glucose levels and HbA1c were signiﬁ-
cantly higher in diabetic animals when compared to control
rat values, whereas Hb levels were decreased signiﬁcantly in
d i a b e t i cr a t sc o m p a r e dt oc o n t r o lr a tv a l u e s .T r e a t m e n to f
diabetic rats with SMV nonsigniﬁcantly increased total Hb
and signiﬁcantly (P<0.05) decreased blood glucose level
and HbA1c compared to untreated diabetic rat values. On
the other hand, glibenclamide signiﬁcantly reduced fasting
bloodglucoselevelandHbA1c whencomparedwithuntreat-
ed diabetic animals (P<0.001).
3.4. Plasma Lipid Proﬁle. In diabetic rats, there was a signif-
icant increase (P<0.001) in TC and TG levels by 42 and
124%, respectively, and signiﬁcant decrease in HDL-C. Oral
administration of SMV signiﬁcantly decreased the levels of
TCandTGandincreasedthelevelsofHDL-Cindiabeticrats
compared to untreated diabetic ones. Furthermore, results
obtained following treatment with SMV were comparable to
those obtained following glibenclamide treatment (Table 4).
3.5. Serum Creatinine, BUN, and Urine Protein. Figure 1
shows a signiﬁcant increase (P<0.05) in the serum crea-
tinine, BUN, and urine protein in untreated diabetic rats
when compared with control group. STZ induced almost
a twofold increase in the creatinine and urea levels and an
eightfoldincreaseintheurineproteinlevelsoverthecontrols
rats. All the indices were reduced to near control levels when
the SMV was administered to the untreated diabetic rats. In
Table 4: Eﬀect of simvastatin (SMV) and glibenclamide supple-
mentation on serum total cholesterol, high-density lipoprotein-
cholesterol (HDL-C) and triglycerides for rats in diﬀerent experi-
mental groups.
Groups
Total
cholesterol
(mg/dL)
HDL-C
(mg/dL)
Triglycerides
(mg/dL)
Control 77.4 ± 4.4 42.5 ± 1.3 57.3 ± 1.8
SMV 70.8 ± 3.1 44.6 ± 1.6 50.1 ± 2.1
Diabetic 110.3 ± 5.1∗ 31.2 ± 2.2∗ 128.6 ± 3.6∗
Diabetic + SMV 80.2 ± 2.9∗# 55.7 ± 2.8∗# 61.2 ± 2.4#
Diabetic +
Glibenclamide 89.3 ± 3.6∗# 45.3 ± 1.9# 68.7 ± 3.6∗#
Data are the mean ± SEM for eight animals in each group.
∗P<0.001 compared with the control group.
#P<0.05 compared with the untreated diabetic group.
the case of control and SMV only treated rats, the levels of
the abovementioned parameters remained unaltered.
3.6. Serum ALT, AST, and Total Bilirubin. The eﬀect of SMV
and glibenclamide on STZ-induced liver damage in rats with
reference to the changes in the level of AST, ALT, and total
bilirubin is shown in Figure 2. Diabetic rats showed sig-
niﬁcant increase in the levels of AST, ALT and total bilirubin
as compared to the normal control group, whereas blood
samples analysis from the animals treated with SMV or gli-
benclamideshowedsigniﬁcantdecreaseinthelevelsofserum
markerenzymes andtotal bilirubin tothe nearnormal value.
3.7. Plasma Nonenzymatic Antioxidants. T h el e v e l so fn o n -
enzymatic antioxidants in normal and diabetic rats are given
in Figure 3. There was a signiﬁcant (P<0.05) decrease in
the levels of GSH (13.8 ± 0.78 versus 23.6 ± 1.72mg/dL) and
vitamin C (0.82 ± 0.06 versus 1.63 ± 0.11mg/dL) in diabetic
control rats than normal rats. Oral administration of SMV
and glibenclamide to diabetic rats leads to a signiﬁcant (P<
0.05) increase in the plasma levels of GSH and vitamin C.
3.8. Reduced GSH in Liver and Kidney Homogenates. Figures
4(a) and 4(b) show the GSH content in liver and kidney
homogenates of control and diabetic rats. There was a sig-
niﬁcantdecreaseintheconcentrationofGSHintheliverand
kidney homogenates (50 and 36%, resp.) in diabetic rats
compared with control rats. Administration of SMV and gli-
benclamide increased the GSH content in the liver (74 and
44%, resp.) and kidney homogenates (35 and 18%, resp.) of
the diabetic group of rats. The eﬀect was more pronounced
in the group of rats treated with SMV and not signiﬁcant in
the groups treated with glibenclamide (P>0.05).
3.9. LPO. Liver and kidney TBARS levels, an index of LPO,
werehigherindiabeticrats(3.96±0.36and5.14±0.12nmol/
mg protein, resp.) compared with control rats (2.03 ± 0.14
and 1.96 ± 0.11nmol/mg protein, resp.) and markedly de-
creased (P<0.001) by SMV. Level of TBARS in liver and6 Journal of Lipids
0
1
2
3
4
S
e
r
u
m
c
r
e
a
t
i
n
i
n
e
(
m
g
/
d
L
)
∗#
∗
∗
#
(a)
0
10
20
30
40
B
l
o
o
d
u
r
e
a
n
i
t
r
o
g
e
n
(
m
g
/
d
L
)
∗
∗
#
∗#
(b)
0
2
4
6
SMV
Diabetic
Diabetic + SMV
U
r
i
n
e
p
r
o
t
e
i
n
(
m
g
/
d
L
)
∗
∗
#
#
Diabetic + glibenclamide
Control
(c)
Figure 1: Eﬀect of simvastatin (SMV) and glibenclamide treatment on serum creatinine (a), blood urea (b), and urinary protein (c), in
normal and streptozotocin-induced diabetic rats. Data are expressed as means ± SEM (n = 8). ∗Signiﬁcantly diﬀerent from control group
(P<0.01). #Signiﬁcantly diﬀerent from diabetic-untreated group (P<0.01).
kidney had no signiﬁcant change in healthy rats treated with
SMV; see Figures 5(a) and 5(b).
3.10. Antioxidant Enzymes. Figures 6 and 7 show SOD, CAT,
and GSH-Px activities in liver and kidney homogenates of
control and diabetic rats. In the diabetic group, there was
a signiﬁcant reduction in SOD, CAT, and GSH-Px activities
in the liver (64, 49, and 40%, resp.) and kidney (43, 34, and
39%, resp.) homogenates compared with the control group.
Treatment with SMV and glibenclamide increased SOD,
CAT, and GSH-Px activity in diabetic rats.
4. Discussion
Diabetes mellitus is a highly prevalent chronic illness and
it has been reported that increased oxidative stress may
play a role in the pathogenesis and progression of diabetic
tissue damage [39, 40]. Chronic hyperglycemia in diabetic
patients or animals can cause oxidative stress, depleting the
activity of the antioxidative defense system and resulting in
elevated levels of oxygen-free radicals [6]. Consequences of
oxidative stress induce the production of highly ROS that are
toxic to cells, particularly the cell membrane in which these
radicals interact with the lipid bilayer and produce lipid per-
oxides and lead to organs oxidative damage [41]. Reduced
oxidative stress in the diabetic condition had been observed
in experimental animals following the administration of cer-
tain antioxidants [42].
In the current study, administration of STZ resulted in
a signiﬁcant increase in the blood glucose level. Persistent
hyperglycemia results in glycation of Hb that leads to the for-
mation of HbA1c [43]. The observed increase in the levels of
HbA1c with a concomitant decrease in Hb in the experimen-
tal diabetic rats implies the oxidation of sugars, extensive
damage to both sugars and proteins in the circulation,
and reinforcing the cycle of oxidative stress and dam-
age. Inouye et al. have reported a signiﬁcant correla-
tion between glycated hemoglobin and diﬀerent markers
of lipid peroxidation [44, 45]. Agents with antioxidant
or free radical scavenging power have been shown toJournal of Lipids 7
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Figure 2: Eﬀect of simvastatin (SMV) and glibenclamide treatment on (a) serum aspartate aminotransferase (AST), (b) alanine amino-
transferase (ALT) and (c) total bilirubin in normal and strep-tozotocin-induced diabetic rats. Data are expressed as means ± SEM (n = 8).
∗Signiﬁcantly diﬀerent from control group (P<0.01). #Signiﬁcantly diﬀerent from diabetic-untreated group (P<0.01).
0
10
20
30
40
∗
#
∗#
G
l
u
t
a
t
h
i
o
n
e
(
m
g
/
d
L
)
(a)
0.5
1.5
2.5
0
2
1
V
i
t
a
m
i
n
C
(
m
g
/
d
L
)
SMV
Diabetic
Diabetic + SMV
∗
# #
Diabetic + glibenclamide
Control
(b)
Figure 3:Eﬀectofsimvastatin(SMV)andglibenclamidetreatmenton(a)plasmaglutathioneand(b)vitaminCinnormalandstrepto-zoto-
cin-induced diabetic rats. Data are expressed as means ± SEM (n = 8). ∗Signiﬁcantly diﬀerent from control group (P<0.01). #Signiﬁcantly
diﬀerent from diabetic-untreated group (P<0.01).8 Journal of Lipids
0
10
20
30
40
50
G
S
H
(
µ
m
o
l
/
m
g
p
r
o
t
e
i
n
)
∗
#
#
(a) Liver
0
10
20
30
40
50
SMV
Diabetic
Diabetic + SMV
∗
#
#
G
S
H
(
µ
m
o
l
/
m
g
p
r
o
t
e
i
n
)
Diabetic + glibenclamide
Control
(b) Kidney
Figure 4: Eﬀect of simvastatin (SMV) and glibenclamide treatment
on (a) liver glutathione and (b) kidney glutathione in normal and
streptozotocin-induced diabetic rats. Data are expressed as means
± SEM (n = 8). ∗Signiﬁcantly diﬀerent from control group (P<
0.01). #Signiﬁcantly diﬀerent from diabetic-untreated group (P<
0.01).
inhibit oxidative reactions associated with glycation [46].
In this regard treatment with SMV signiﬁcantly reversed the
imbalance in the oxidative stress status. The antidiabetic
eﬀect observed in the present study may be attributed to
pleotropic eﬀect of statin as improvement in insulin signal-
ing pathway, protection of β-cell from oxidative stress, and
increase in insulin release [47, 48]. Recently, it is proven
that statins can inhibit dipeptidyl peptidase IV (DPP-IV)
[49]. DPP-IV is serine protease, responsible for degradation
of Glucagon like peptide 1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP). GLP-1 and GIP play im-
portant role in glucose homeostasis as both are responsible
for 70% of insulin secretion after meal by inhibiting DPP-IV.
Therefore statins can increase insulin secretion.
In the present study, lipid proﬁle markers, such as TC,
TG, and HDL-C, further conﬁrm that there is a strong cor-
relation between oxidative stress and diabetes occurrence.
Increased fasting and postprandial plasma levels of TG, free
fatty acids, and cholesterol are common in diabetes and they
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Figure 5: Eﬀect of simvastatin (SMV) and glibenclamide treatment
on liver thiobarbituric acid reactive substances (TBARS) in liver (a)
and kidney (b) in normal and streptozotocin-induced diabetic rats.
Dataareexpressedasmeans ±SEM(n = 8). ∗Signiﬁcantlydiﬀerent
from control group (P<0.01).
are known to generate ROS [50, 51]. Antioxidants such as
resveratrol, vitamin C, and vitamin E have been reported to
reduce STZ-induced oxidative damage [5, 52]. Similarly, we
observed that administration of SMV signiﬁcantly restored
abnormal levels of lipid proﬁle markers in blood in diabetic
rats. This suggests that SMV may improve lipid dysfunction
of diabetic rats and retard development of diabetic compli-
cations. Our results are in agreement with previous reports
[19, 53].
Elevated activities of serum AST, ALT, and total bilirubin
a r eac o m m o ns i g no fl i v e rd i s e a s ea n da r eo b s e r v e dm o r e
frequently among people with diabetes than in the general
population [54]. SMV treatment prevented the increase in
these enzymatic activities in serum that was caused by STZ
administration. Our results are in agreement with those of
Imaedaetal. [55]whoalsofoundthatantioxidantsinhibited
the increase in serum levels of AST and ALT in STZ-treated
mice. Increased serum levels of urea and creatinine, indica-
tors of impaired renal function [19], observed in the diabetic
rats might indicate renal damage. Treatment with SMVJournal of Lipids 9
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Figure 6: Eﬀect of simvastatin (SMV) and glibenclamide treatment on liver enzymatic antioxidants: (a) SOD, (b) CAT, and (c) GSH-Px in
normal and streptozotocin-induced diabetic rats. Data are expressed as means ± SEM (n = 8). SOD: superoxide dismutase: CAT, catalase;
GSH-Px: glutathione peroxidase. ∗Signiﬁcantly diﬀerent from control group (P<0.01). #Signiﬁcantly diﬀerent from diabetic-untreated
group (P< 0.01).
signiﬁcantlydecreasedserumcreatinineandurea.Thesedata
suggest that SMV may help in the repair of renal damage.
During diabetes, an increased oxidative stress in certain
tissues may lead to a rise in the rate of LPO [8]. The forma-
tion of the lipid peroxide product, TBARS, was measured in
tissue as an index of increased LPO in diabetic liver and kid-
neys [56]. In the present study, the increased TBARS content
of diabetic rats suggests that peroxidative injury may be in-
volved in the development of diabetic complications. TBARS
levels in liver and kidneys were signiﬁcantly decreased in the
SMVandglibenclamide-treatedgroupscomparedtothedia-
betic control rats. Recently, agents with antioxidant or free
radical scavenging power have been shown to inhibit oxida-
tive reactions associated with LPO [5, 52]. The above result
suggests that the SMV may exert antioxidant eﬀects and pro-
tect the tissues from LPO.
Nonenzymatic antioxidants such as GSH and vitamin C
play an excellent role in preventing the cells from oxidative
damage. GSH is an intracellular thiol rich tripeptide, which
plays a major role in the protection of cells and tissue struc-
tures [57]. GSH is required for the recycling of vitamin C
[58] and acts as a substrate for GSH-Px that is involved in
preventing the deleterious eﬀect of free radicals [59]. In our
study, diabetic rats exhibited decreased level of GSH, which
might be due to increased utilization of GSH for scavenging
free radicals by GSH-Px. Administration of SMV reversed
GSH level in plasma of diabetic rats, which could be due to
the low peroxidisability and thus its low utilization. The pre-
sent ﬁndings of decreased GSH in liver and kidneys are con-
sistent with the studies of Panda et al. [56].
Vitamin C is a well-known physiological hydrophilic
antioxidantinplasma,becauseitdisappearsfasterthanother
antioxidantswhenplasmaisexposedtoROS[60].Theobser-
ved signiﬁcant decrease in the level of plasma vitamin C
could be caused by increased utilization of vitamin C as an
antioxidant defense against ROS or by a decrease in GSH,
which is required for the recycling of vitamin C. Treatment
with SMV brought vitamin C to near normal levels which
could be as a result of decreased membrane damage as evi-
denced by the antioxidant nature.10 Journal of Lipids
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Figure 7: Eﬀect of simvastatin (SMV) and glibenclamide treatment on kidney enzymatic antioxidants: (a) SOD, (b) CAT, and (c) GSH-Px
in normal and streptozotocin-induced diabetic rats. Data are expressed as means ± SEM (n = 8). SOD: superoxide dismutase; CAT: catalase;
GSH-Px: glutathione peroxidase. ∗Signiﬁcantly diﬀerent from control group (P<0.01). #Signiﬁcantly diﬀerent from diabetic-untreated
group (P<0.01).
Simvastatinisalipophiliccompoundthatmayhavemore
potent eﬀects on extrahepatic sites [61]. It has a short half-
life time of about 2h and is cleared by extensive metabolism
in the intestinal gut and liver by cytochrome (CYP) 3A [62].
In the present study, SMV showed antioxidant eﬀect both in
vitro and in vivo. ROS-induced oxidative damage has been
implicated in the pathogenesis of several disorders, including
d i a b e t e sm e l l i t u s[ 63]. Oxidative stress is the imbalance bet-
ween production and removal of ROS. Increased oxidative
stress, which contributes substantially to the pathogenesis of
diabetic complications, is the consequence of either enhanc-
ed ROS production or attenuated ROS-scavenging capacity.
Several studies have demonstrated both lower nonenzymatic
antioxidant levels and enzymatic antioxidant activities in
streptozotocin-induced diabetic rats [9, 56]. Recently, Seﬁ
et al. [64] have reported an elevated LPO and lowered anti-
oxidants in streptozotocin-induced diabetes mellitus.
Enzymatic antioxidants (SOD, CAT, and GSH-Px) form
the ﬁrst line of the antioxidant defense mechanism to protect
the organism from ROS-mediated oxidative damage [58].
In the current study, SOD, CAT and GSH-Px showed lower
activities in liver and kidney during diabetes and the results
agree well with the earlier published data [65, 66]. The de-
creased activities of SOD, CAT, and GSH-Px may be a res-
ponsetoincreasedproductionofH2O2 andO2
.− bytheauto-
oxidation of the excess of glucose and nonenzymatic glyca-
tion of proteins [67]. Pigeolet et al. [68] have reported the
partial inactivation of these enzyme activities by hydroxyl
radicals and hydrogen peroxide. The decreased activity of
SOD and CAT could also be due to their decreased protein
expressionlevelsinthediabeticcondition,asrecentlyreport-
ed in liver [69]. The decreased GSH-Px activity represents
a compensatory mechanism to degrade H2O2.T r e a t m e n to f
the diabetic rats with SMV restored the altered antioxidant
enzyme activities signiﬁcantly (P<0.001).
Inconclusion,thepresentinvestigationshowedthatSMV
may possess an antioxidant activity and it also protects LPO
and enhances its eﬀect on enzymatic antioxidant (SOD,Journal of Lipids 11
CAT,andGSH-Px)andnonenzymaticantioxidant(GSHand
vitamin C) defense. This activity contributes to the protec-
tion against oxidative damage in STZ-induced diabetes.
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